Brokerages predict that STERIS (NYSE:STE) will announce $640.43 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for STERIS’s earnings, with the highest sales estimate coming in at $644.40 million and the lowest estimate coming in at $638.20 million. STERIS posted sales of $607.96 million in the same quarter last year, which would suggest a positive year over year growth rate of 5.3%. The company is expected to announce its next earnings results on Tuesday, August 14th.
According to Zacks, analysts expect that STERIS will report full-year sales of $2.75 billion for the current financial year, with estimates ranging from $2.75 billion to $2.76 billion. For the next financial year, analysts expect that the business will post sales of $2.90 billion per share, with estimates ranging from $2.88 billion to $2.91 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for STERIS.
STERIS (NYSE:STE) last issued its quarterly earnings results on Wednesday, May 9th. The medical equipment provider reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.02. The business had revenue of $716.00 million during the quarter, compared to analyst estimates of $703.37 million. STERIS had a net margin of 11.10% and a return on equity of 11.55%. The business’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.11 earnings per share.
A number of brokerages recently issued reports on STE. Zacks Investment Research lowered shares of STERIS from a “buy” rating to a “hold” rating in a research note on Tuesday, May 1st. KeyCorp restated a “buy” rating and issued a $103.00 price target on shares of STERIS in a research note on Thursday, February 8th. Finally, Northcoast Research set a $102.00 price target on shares of STERIS and gave the stock a “buy” rating in a research note on Thursday, February 8th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $86.80.
In other STERIS news, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the business’s stock in a transaction on Monday, March 12th. The shares were sold at an average price of $95.50, for a total transaction of $955,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Cynthia L. Feldmann sold 3,218 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $91.35, for a total transaction of $293,964.30. Following the sale, the director now owns 11,214 shares of the company’s stock, valued at approximately $1,024,398.90. The disclosure for this sale can be found here. In the last 90 days, insiders sold 95,607 shares of company stock valued at $8,950,955. Insiders own 2.55% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. Captrust Financial Advisors bought a new stake in STERIS during the fourth quarter valued at $101,000. Meeder Asset Management Inc. increased its stake in STERIS by 1,122.4% during the fourth quarter. Meeder Asset Management Inc. now owns 1,198 shares of the medical equipment provider’s stock valued at $104,000 after purchasing an additional 1,100 shares during the last quarter. YorkBridge Wealth Partners LLC bought a new stake in STERIS during the fourth quarter valued at $113,000. Hanson & Doremus Investment Management bought a new stake in STERIS during the first quarter valued at $140,000. Finally, Zions Bancorporation bought a new stake in STERIS during the first quarter valued at $200,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.
Shares of NYSE:STE opened at $103.46 on Monday. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.48 and a quick ratio of 1.97. The firm has a market capitalization of $8.78 billion, a P/E ratio of 24.93 and a beta of 1.12. STERIS has a 12-month low of $74.94 and a 12-month high of $104.31.
The business also recently declared a quarterly dividend, which will be paid on Thursday, June 28th. Investors of record on Friday, June 8th will be paid a $0.31 dividend. The ex-dividend date of this dividend is Thursday, June 7th. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.20%. STERIS’s dividend payout ratio (DPR) is presently 29.88%.
STERIS Company Profile
STERIS plc develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. The company's Healthcare Products segment offers steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers, as well as liquid chemical sterilant processing systems; automated washer/disinfector systems; general and specialty surgical tables, surgical and examination lights, equipment management systems, operating room storage cabinets, warming cabinets, scrub sinks, and other accessories; and gastrointestinal devices and accessories.
Get a free copy of the Zacks research report on STERIS (STE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.